Role of Psychological support in sustaining Antidepressants effects in Psilocybin - Assisted Clinical

Depression is a common mental health challenge that affects thinking, behavior, and quality of life, and standard antidepressants do not work for everyone, often causing side effects or delayed responses. Psilocybin, a compound from certain mushrooms, targets serotonin receptors in the brain, lifting mood and promoting neural adaptability. Animal studies with mice, rats, zebrafish, and fruit flies show reduced depression- and anxiety-like behaviors after psilocybin. Clinical trials using synthetic COMP360 in people with treatment-resistant depression report meaningful improvement within days that lasted for weeks. Psychological support before, during, and after the experience is as important as the compound itself, making psilocybin-assisted therapy a whole-person approach.

Study at a glance

Abstract

Depression is one of the most common mental health challenges people face today. It goes beyond just feeling sad — it shapes the way a person thinks, behaves, and experiences the world around them. The persistent low mood, the fading interest in things that once brought joy, the fog that makes even simple decisions feel overwhelming — all of it quietly chips away at a person's quality of life. For decades, antidepressants have been the go-to solution. But the reality is, they don't work for everyone. Some people wait weeks before noticing any change. Others deal with side effects that feel like trading one problem for another. It's a gap that researchers and clinicians have long been trying to close. That's where psilocybin enters the conversation. Found naturally in certain mushrooms, this compound has been drawing serious scientific attention — not as a curiosity, but as a genuine candidate for treating depression. What makes it particularly intriguing is how it works: it targets serotonin receptors in the brain, helping to lift mood, improve how we process emotions, and even encourage the brain's own ability to adapt and rewire itself. Animal studies have painted an encouraging picture. Mice, rats, zebrafish, and even fruit flies have all shown measurable reductions in depression- and anxiety-like behaviors following psilocybin. And it's not just the lab — clinical trials using a synthetic version called COMP360 have shown real promise in people with treatment-resistant depression, with some patients reporting meaningful improvement within days that lasted for weeks. One thing these studies make clear, though, is that the medicine alone isn't the whole story. The psychological support surrounding the experience — before, during, and after — appears to be just as important as the compound itself. It's this combination of pharmacology and human care that sets psilocybin-assisted therapy apart, offering something closer to a wholeperson approach to healing. Researchers are now focused on making this treatment safer, more consistent, and ultimately more accessible to those who need it most